Kayne Anderson Rudnick Investment Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.7K Sell
126
-14
-10% -$2.9K ﹤0.01% 676
2026
Q1
$31.4K Sell
140
-3
-2% -$748 ﹤0.01% 624
2025
Q4
$34.5K Buy
143
+3
+2% +$767 ﹤0.01% 619
2025
Q3
$38.3K Sell
140
-9
-6% -$2.46K ﹤0.01% 620
2025
Q2
$38.4K Buy
149
+15
+11% +$3.58K ﹤0.01% 624
2025
Q1
$30K Sell
134
-6
-4% -$1.4K ﹤0.01% 623
2024
Q4
$32.2K Buy
140
+6
+4% +$1.45K ﹤0.01% 588
2024
Q3
$32.7K Hold
134
﹤0.01% 583
2024
Q2
$25.6K Hold
134
﹤0.01% 575
2024
Q1
$26.5K Sell
134
-1
-0.7% -$183 ﹤0.01% 571
2023
Q4
$23.2K Buy
135
+15
+13% +$2.31K ﹤0.01% 564
2023
Q3
$17.7K Hold
120
﹤0.01% 565
2023
Q2
$26.2K Hold
120
﹤0.01% 543
2023
Q1
$26.3K Buy
120
+1
+0.8% +$217 ﹤0.01% 530
2022
Q4
$24.8K Hold
119
﹤0.01% 547
2022
Q3
$26K Buy
+119
New +$27.1K ﹤0.01% 515

Other funds holding RMD

Kayne Anderson Rudnick Investment Management's RMD Position: Q2 2026 in Review

Kayne Anderson Rudnick Investment Management reduced its ResMed (RMD) stake by 10% in Q2 2026, selling an estimated $2.9K and leaving 126 shares worth $24.7K. The position accounts for ﹤0.01% of the portfolio, ranked #676.

Kayne Anderson Rudnick Investment Management first reported a position in RMD in Q3 2022 and has held it in 16 quarters since. The position peaked at $38.4K in Q2 2025. 882 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Kayne Anderson Rudnick Investment Management held 126 shares of ResMed worth $24.7K as of Q2 2026.
  • Kayne Anderson Rudnick Investment Management sold 14 ResMed shares in Q2 2026, an estimated $2.9K.
  • ResMed made up ﹤0.01% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #676 holding.
  • Kayne Anderson Rudnick Investment Management first reported a position in ResMed in Q3 2022 and has held it in 16 quarters since.
  • Kayne Anderson Rudnick Investment Management's ResMed position peaked at $38.4K in Q2 2025.
  • 882 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.